![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsors and Collaborators: |
BeerYaakov Mental Health Center Lundbeck Israel |
---|---|
Information provided by: | BeerYaakov Mental Health Center |
ClinicalTrials.gov Identifier: | NCT00148447 |
The aim of this study is to evaluate the therapeutic effect of escitalopram in the treatment of negative symptoms in schizophrenia patients in a double-blind placebo-controlled study.
Condition | Intervention | Phase |
---|---|---|
Schizophrenia |
Drug: escitalopram |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety Study |
Official Title: | Placebo-Controlled Trial of Cipralex in the Treatment of Negative Symptoms in Schizophrenia |
Estimated Enrollment: | 40 |
Study Start Date: | November 2004 |
Estimated Study Completion Date: | September 2005 |
The aim of this study is to evaluate the therapeutic effect of escitalopram (cipralex) in the treatment of negative symptoms in schizophrenic patients receiving either typical or the newer atypical antipsychotics (olanzapine and risperidone) in a double-blind placebo-controlled study. As there is no drug treatment that is considered as first-line treatment in the treatment of negative symptoms, we thought that the comparison with placebo is plausible. However, it is important to note that the patients will receive the commonly used treatment for their disorder (i.e. antipsychotic medication).
Ages Eligible for Study: | 18 Years to 60 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Israel | |
Iulian Iancu | |
Beer Yaakov, Israel, POB 1 |
Principal Investigator: | Iulian Iancu, M.D. | Beer Yaakov Mental Health Center |
Study Chair: | Moshe Kotler, M.D. | Beer Yaakov Mental Health Center |
Study ID Numbers: | Escitalopram-118CTIL |
Study First Received: | September 6, 2005 |
Last Updated: | May 2, 2007 |
ClinicalTrials.gov Identifier: | NCT00148447 |
Health Authority: | Israel: Israeli Health Ministry Pharmaceutical Administration |
negative symptoms depression ssri schizophrenia |
Schizophrenia Depression Mental Disorders Psychotic Disorders Dexetimide |
Depressive Disorder Citalopram Serotonin Schizophrenia and Disorders with Psychotic Features |
Parasympatholytics Neurotransmitter Uptake Inhibitors Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Cholinergic Antagonists Anti-Dyskinesia Agents Physiological Effects of Drugs Psychotropic Drugs Antiparkinson Agents Cholinergic Agents |
Serotonin Uptake Inhibitors Pharmacologic Actions Muscarinic Antagonists Serotonin Agents Autonomic Agents Therapeutic Uses Peripheral Nervous System Agents Antidepressive Agents, Second-Generation Central Nervous System Agents Antidepressive Agents |